Study #2022-0868
A single-arm, multicenter study to assess the efficacy, safety, and tolerability of Ropeginterferon alfa-2b-njft (P1101) in adult patients with essential Thrombocythemia
MD Anderson Study Status
Not Accepting
Treatment Agent
Ropeginterferon alfa-2b-njft (P1101)
Description
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Essential Thrombocythemia
Study phase:
Phase II
Physician name:
Lucia Masarova
Department:
Leukemia
For general questions about clinical trials:
1-877-364-0962
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.